Author
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteORCID 0000-0001-7796-0251Unclaimed ORCID profile · follow to get notified of new preprints
5 papers
Recent·Most cited
Darren Lee, Yazan Abu-Shihab, Kate Plas…·Linde A. Miles
This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.
Morgan Drucker, Darren Lee, M. B. Bowman…·Linde A. Miles
This study uses single-cell multiomic analysis to reveal genotype-immunophenotype relationships and clonal evolution in NPM1-mutant AML across disease stages.
Sydney Fobare, Chia Sharpe, K. R. Quinn…·John C. Byrd
This study identifies PTPN11 mutations as potential initiating events in AML when paired with NPM1 mutations, revealing their co-driver role and immune diversity in patient samples.
Dimitrios Papaioannou, Amog P. Urs, Rémi Buisson…·Ramiro Garzon
This study identifies circPCMTD1 as a circular RNA that promotes leukemic cell proliferation by enhancing DNA damage response tolerance through a novel peptide product.
Etienne Sollier, Anna Riedel, Umut H. Toprak…·Christoph Plass
Pyjacker detects enhancer hijacking in AML, identifying MNX1 activation via 7q deletion as a novel oncogenic mechanism.